Key clinical point: Prior antibiotic exposure may hinder the efficacy of checkpoint inhibitors.
Major finding: Median overall survival was 2 months with prior antibiotic exposure versus 26 months without.
Study details: A prospective, observational study of 196 patients with various cancers treated with immune checkpoint inhibitors.
Disclosures: The study was internally supported. Dr. Pinato reported receiving grant funding from Merck and Bristol-Myers Squibb unrelated to the study, as well as honoraria from ViiV Healthcare.
Pinato DJ et al. ASCO-SITC,.